News

The Magnum Group Inc. has been hired to solicit offers for the assets of NovaVision Inc., which filed for Chapter 7 bankruptcy in Florida April 28 after more than seven years of continuous operation.

Bausch + Lomb (B+L) is voluntarily recalling an eye vitamin (PreserVision Eye Vitamin AREDS 2 Formula with Omega 3) after receiving ?a small number of reports predominantly within a specific age group, age 70 and older, who reported difficulty swallowing or a choking sensation when taking the soft gel,? according to the company.

Alcon Laboratories is recalling a microsurgical system (Constellation Vision System) after identifying software and hardware issues associated with unexpected loss of power, unintended system error messages, unresponsive touch screens, and system setting and infusion performance problems.

The FDA has cleared a new C-loop, single-piece hydrophilic acrylic IOL (Softec ONE, Lenstec) for the treatment of patients with cataracts.

The FDA has granted approval for an abbreviated new drug application to market a generic version of azelastine ophthalmic solution 0.05% (Optivar, Meda Pharmaceuticals), according to Sun Pharmaceutical Industries.

EyeGate Pharma has begun enrolling patients in the ALLUVION (EvALuation of Dexamethasone Phosphate DeLivered by OcUlar Iontophoresis for the Treatment of Dry Eye in the Controlled Adverse EnVIrONment Model) pivotal phase III study of EGP-437 for the treatment of dry eye syndrome.

The National Eye Institute (NEI) has launched an ancillary study to the ongoing Age-Related Eye Disease Study 2, which has the aim of determining whether oral supplementation of lutein/zeaxanthin and omega-3 fatty acids can further slow the progression of vision loss from age-related macular degeneration.

A new silicone hydrogel daily disposable contact lens (1-Day Acuvue TruEye, Vistakon) is now available in the United States, after having been cleared by the FDA in June.

Ophthalmic Women Leaders and Women In Ophthalmology announce a joint partnership in presenting the WIO Summer Symposium, Aug. 12 to 15, at the Pinehurst Resort in Pinehurst, NC.

Lux Biosciences Inc. announced the appointment of Dean Mitchell as president and chief executive officer.

Nicholas J. Volpe, MD, professor and holder of the Adele Niessen Chair in Ophthalmology at the University of Pennsylvania School of Medicine, has been named the new chairman of ophthalmology at Northwestern Medicine, effective Sept 1.

Bausch + Lomb has named Robert E. Grant chief executive officer and president of its global surgical business, effective Aug. 1.

Alimera Sciences has submitted a new drug application to the FDA for its investigational sustained drug delivery system releasing sub-microgram levels of fluocinolone acetonide (Iluvien) for the treatment of diabetic macular edema.

VisionCare Ophthalmic Technologies Inc. announced the FDA approval of the company?s Implantable Miniature Telescope (by Dr. Isaac Lipshitz) to improve vision in patients with end-stage age-related macular degeneration.

The FDA has approved ranibizumab injection (Lucentis, Genentech) for the treatment of macular edema following retinal vein occlusion after a 6-month priority review.

Alcon Laboratories announced that it has entered into a definitive agreement to acquire LenSx Lasers Inc., a privately held company located in Aliso Viejo, CA, that developed the first femtosecond laser to receive FDA clearance for use as a part of cataract surgery.

After 4 years of follow-up in a clinical trial, the angle-supported foldable acrylic phakic IOL is continuing to provide patients treated for moderate to high myopia with good visual acuity thanks to accurate predictability, a stable refractive outcome, and good safety.

Interim results from analyses of data collected in the ongoing LASIK in U.S. Naval Aviator Study show advances in excimer and femtosecond laser technology are contributing to better clinical results.

Since its earliest days, the Jules Stein Eye Institute at the University of California-Los Angeles has been known as a center for vision science research, with the goal of preserving and restoring eyesight.

Long-term follow-up in a cohort of eyes with the dual-optic accommodating IOL implanted supports its use as a viable option for presbyopic correction after cataract surgery.

Initial clinical results indicate the safety and efficacy of Descemet's membrane endothelial keratoplasty as a minimally invasive alternative for eyes requiring transplantation because of dysfunctional endothelium.

In the interest of providing both good-quality vision in addition to a full range of functional visual acuity for patients interested in a presbyopic IOL, the latest aspheric version of an accommodating IOL may be considered a better option relative to its multifocal competitors.

Intraoperative wavefront aberrometry using a proprietary system demonstrates the ability to measure refractive error accurately in aphakic eyes and represents technology that may improve accuracy of IOL power outcomes after cataract surgery.

Bausch + Lomb recently purchased the assets and U.S. rights for ganciclovir ophthalmic gel 0.15% from Sirion Therapeutics.

A mix-and-match approach to multi-focal IOL implantation using lenses based on two different optical principles provides excellent functional outcomes.

The author has always thought that advanced machines could not replace humans - until recently.

After enduring a week-long 21.2% pay cut, ophthalmologists and other physicians who see Medicare patients will receive a 2.2% pay increase, retroactive to June 1 through Nov. 30.

Robert E. Grant will join Bausch + Lomb on August 1 as its chief executive officer and president of the company's global surgical business.